TPMTYour two copies: *1/*1
Normal metabolizer
Both copies work normally.
Breaks down thiopurines such as azathioprine and mercaptopurine.
This result doesn't change the label.
Example report. Made from Leslie Knope's DNA data so you can see what yours will look like. Get your own report
Oncology · ChemotherapiesExample report
Thioguanine
Lanvis, Tabloid
Use as directed
Both genes that affect this drug look normal, so a standard starting dose is expected.
The genes behind this label
The guidelines read 2 genes for thioguanine. Each card shows the two copies this person inherited and what they mean.
NUDT15Your two copies: *1/*1
Normal metabolizer
Both copies work normally.
Breaks down the active form of thiopurines such as azathioprine.
This result doesn't change the label.
What the guidelines say
What each guideline says about your result.
TPMTNormal metabolizerNUDT15Normal metabolizer
CPIC guideline, both genes together
Evidence: strongRead the guideline (Clinical Pharmacogenetics Implementation Consortium, opens in a new tab)
- In plain words
- Both genes that affect this drug look normal, so a standard starting dose is expected.
- What it means
- Both TPMT and NUDT15 predict normal thiopurine metabolism and a normal risk of myelosuppression.
- What the guideline suggests
- Initiate therapy with standard starting dose of thioguanine (e.g., 40 mg/m2/day for malignancy). During therapy, adjust the doses of myelosuppressive agents, as per standard clinical practice. It usually takes at least 2 weeks of stable dosing to reach steady state after each dose adjustment.
From the combined TPMT and NUDT15 table in CPIC's thiopurine guideline.
CPIC reads your TPMT and NUDT15 results together for thioguanine, so this label reflects both genes.
About thioguanine
Thioguanine (6-thioguanine) is a thiopurine tablet used to induce and consolidate remission in acute myeloid leukemia, which the FDA label calls acute nonlymphocytic leukemia.
- Used for
- Remission induction and consolidation in acute myeloid (nonlymphocytic) leukemia; the label advises against maintenance or other long-term continuous use because of liver toxicity
Others in oncology
Compare all 13 oncology- BelinostatBeleodaq Use as directed
- BelzutifanWelireg Use as directed
- CapecitabineXeloda, Xitabin, Kapetral Use as directed
- ErdafitinibBalversa Use as directed
- FluorouracilAdrucil, Carac Use as directed
- GefitinibIressa Use with caution
- IrinotecanCamptosar, Onivyde Use as directed
- MercaptopurinePurinethol Use as directed
Don't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.